轮状病毒灭活疫苗(Vero细胞)在18-49岁健康成人中随机双盲安慰剂对照Ⅰ期临床试验的安全性及免疫原性初步观察
在河南省睢县开展的Ⅰ期随机双盲安慰剂对照试验中,96名18-49岁健康成人按3:1比例随机分配至高、中、低剂量组或安慰剂组接种一剂疫苗。各实验组不良事件发生率与安慰剂组无显著差异,不良事件主要为1-2级;高剂量组中和抗体几何平均滴度高于中、低剂量组。该灭活轮状病毒疫苗在成人中耐受性良好并具有免疫原性。
要点
- 各实验组不良事件发生率与安慰剂组相比无显著差异,主要为1-2级。
- 免疫后28天高剂量组中和抗体几何平均滴度为1055.24,高于中、低剂量组。
- 高剂量组在18-49岁成人中观察到更高的中和抗体水平。
核心结论
- 该新型灭活轮状病毒疫苗在成人中总体耐受性良好,并具有免疫原性。
- 初步观察到高剂量组在18-49岁成人中的中和抗体水平高于中、低剂量组。
研究设计与样本
- 在河南省睢县开展的Ⅰ期随机双盲安慰剂对照试验,纳入96名健康成人。
- 受试者按3:1比例随机分配至高剂量组、中剂量组、低剂量组或安慰剂组,接种一剂疫苗或安慰剂。
- 报告每次接种后28天内的不良事件及所有接种后6个月内的严重不良事件。
- 采用微量中和试验检测抗轮状病毒中和抗体几何平均滴度及血清阳转率。
主要发现
- 安慰剂组、低剂量组、中剂量组和高剂量组总不良事件发生率分别为29.17%(12.62%-51.09%)、12.50%(2.66%-32.36%)、50.00%(29.12%-70.88%)和41.67%(22.11%-63.36%),实验组与安慰剂组相比无显著差异。
- 全程免疫后28天,低剂量组中和抗体几何平均滴度为583.01(95%CI:447.12-760.20),中剂量组为899.34(95%CI:601.73-1344.14),高剂量组为1055.24(95%CI:876.28-1270.75)。
- 全程免疫后28天,低剂量组血清特异性IgG几何平均滴度为3444.26(95%CI:2292.35-5175.02),中剂量组为6888.55(95%CI:4426.67-10719.6),高剂量组为7511.99(95%CI:3988.27-14149.0)。
- 全程免疫后28天,低剂量组血清特异性IgA几何平均滴度为2332.14(95%CI:1538.82-3534.45),中剂量组为4800.98(95%CI:2986.64-7717.50),高剂量组为3204.30(95%CI:2175.66-4719.27)。
- 不良事件主要为1-2级,表明该疫苗在健康成人群体中的安全性在可接受范围内。
关键数值与推荐
- 实验组不良事件发生率与安慰剂组相比无显著差异。
- 高剂量组中和抗体几何平均滴度(1055.24)高于中剂量组(899.34)和低剂量组(583.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a phase I, randomized, double-blind, placebo-controlled trial including healthy adults in Sui County, Henan Province, China. Ninety-six adults were randomly assigned to one of three groups (high-dose, medium-dose, and low-dose) at a 3:1 ratio to receive one vaccine dose or placebo. Adverse events up to 28 days after each dose and serious adverse events up to 6 months after all doses were reported. Geometric mean titers and seroconversion rates were measured for anti-rotavirus neutralizing antibodies using microneutralization tests. The rates of total adverse events in the placebo group, low-dose group, medium-dose group, and high-dose group were 29.17 % (12.62 %-51.09 %), 12.50 % (2.66 %-32.36 %), 50.00 % (29.12 %-70.88 %), and 41.67 % (22.11 %-63.36 %), respectively, with no significant difference in the experimental groups compared with the placebo group. The results of the neutralizing antibody assay showed that in the adult group, the neutralizing antibody geometric mean titer at 28 days after full immunization in the low-dose group was 583.01 (95 % confidence interval [CI]: 447.12-760.20), that in the medium-dose group was 899.34 (95 % CI: 601.73-1344.14), and that in the high-dose group was 1055.24 (95 % CI: 876.28-1270.75). The GMT of serum-specific IgG at 28 days after full immunization in the low-dose group was 3444.26 (95 % CI: 2292.35-5175.02), that in the medium-dose group was 6888.55 (95 % CI: 4426.67-10719.6), and that in the high-dose group was 7511.99 (95 % CI: 3988.27-14149.0). The GMT of serum-specific IgA at 28 days after full immunization in the low-dose group was 2332.14 (95 % CI: 1538.82-3534.45), that in the medium-dose group was 4800.98 (95 % CI: 2986.64-7717.50), and that in the high-dose group was 3204.30 (95 % CI: 2175.66-4719.27). In terms of safety, adverse events were mainly Grades 1 and 2, indicating that the safety of the vaccine is within the acceptable range in the healthy adult population. Considering the GMT and positive transfer rate of neutralizing antibodies for the main immunogenicity endpoints in the experimental groups, it was initially observed that the high-dose group had higher levels of neutralizing antibodies than the medium- and low-dose groups in adults aged 18-49 years. This novel inactivated rotavirus vaccine was generally well-tolerated in adults, and the vaccine was immunogenic in adults (ClinicalTrials.gov number, NCT04626856).
引用
- Wu JY, Zhang W, Pu J, et al. A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity. Vaccine. 2024. PMID: 38796326. doi:10.1016/j.vaccine.2024.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。